Eisai Inc. develops and markets pharmaceuticals to treat a variety of ills. As the US production arm of Eisai Co., its roster includes Alzheimer's treatment Aricept, Aciphex for acid reflux, anti-seizure medication Banzel, anticoagulant Fragmin, lymphoma drug Ontak, and anti-convulsant Zonegran. In addition to neurology, oncology, and vascular ailments, the firm has drug research, development, marketing, and manufacturing programs in areas including infectious disease, inflammation, and critical care. The company supplies its products to health care professionals, pharmacies, and hospitals through wholesale distributors.
The firm's research and development operations span discovery and process research, clinical research, and the formulation and manufacturing of drugs used in clinical research from locations in Pennsylvania and Massachusetts.
The company also operates a commercial drug manufacturing plant in North Carolina that focuses on making solid oral dose medications; additionally, it has a small specialty drug plant in Maryland.
Eisai Inc. has strategic alliances with Pfizer (for Aricept) and Janssen (for AcipHex). It also has a drug discovery collaboration with FORMA Therapeutics to identify novel cancer drug candidates for otherwise difficult targets.
The company has R&D facilities in Massachusetts, New Jersey, North Carolina, and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina.
Sales and Marketing
Eisai Inc. employs a direct sales force of about 900 representatives located in New Jersey; the reps promote its products to doctors and other health care customers.
The company has a product website that offers links to patient support information and details about obesity and BELVIQ. It also utilizes direct-to-consumer advertising on television and in magazines.
Eisai Inc. is part of its parent's Americas Pharmaceutical Business, which provides about a quarter of its total revenues.
Following the loss of US patent protection for top selling drug Aricept, Eisai Inc. has been focused on growth efforts, including R&D and acquisitions. Development efforts focus on neurology, vascular ailments, inflammation, and infectious disease treatments. In 2014 it entered a new collaboration with Biogen Idec to develop and commercialize two clinical candidates for the treatment of Alzheimer's disease.
The company is also focused on cancer treatments (Halaven, Aloxi), as well as BELVIQ, an anti-obesity treatment. In 2014 it launched Fycompa, an epilepsy treatment it developed in-house.
Also in 2014, the company sold the US rights to Zonegran capsules to Concordia Pharmaceuticals.
In 2015 the FDA approved a supplemental New Drug Application (NDA) for BANZEL as a treatment for seizures in pediatric patients with Lennox-Gastaut Syndrome. It also approved Eisai Inc.'s receptor tyrosine kinase inhibitor LENVIMA for the treatment of thyroid cancer.
In 2015 parent Eisai announced realignment efforts to streamline operations. The move primarily impacted Eisai Inc., which will cut about 25% of its workforce. There are no plans to close any offices or facilities.